Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Universal Snake Antivenom
- Development stage
- Preclinical
- Lead developer
- Centivax
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Centivax's Universal Snake Antivenom is a combination therapy currently in preclinical development for the treatment of snakebite envenomation. The therapeutic candidate consists of a three-component cocktail of broadly neutralizing human antibodies combined with varespladib, a small molecule phospholipase A2 (PLA2) inhibitor. The antibodies were derived from the memory B cells of a hyperimmune human donor with extensive snake venom exposure and are designed to target conserved neutralizing epitopes on both long and short snake neurotoxins. In preclinical in vivo studies, the antivenom demonstrated complete protection in mice against whole-venom challenges from all 19 WHO Category 1 and Category 2 snakes, including highly lethal species such as the black mamba, king cobra, and tiger snake.
- Other names
- Centivax Universal Snake Antivenom
02
Targets
L-3FTx (Long-chain three-finger neurotoxin)svPLA2 (Snake venom phospholipase A2)
Beyond the preview
Go deeper on Universal Snake Antivenom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Universal Snake Antivenom.